LAUSR

PD‐L1 expression is associated with differential response in cancers treated with checkpoint inhibitors. Clinical trials for Food and Drug Administration (FDA) approvals of programmed death receptor‐1 (PD‐1)/programmed death ligand‐1 (PD‐L1) inhibitors include limited subgroup analyses based on PD‐L1 expression. We aimed to define the characteristics of PD‐L1 defined subgroups of clinical trials leading to FDA approvals for new indications of PD‐1/PD‐L1 inhibitors. FDA approvals for PD‐1/PD‐L1 inhibitors from January 2014 to December 2020 were identified and the clinical trials leading to each drug approval were reviewed. We collected key variables from publicly available information on FDA website and peer‐reviewed publications of clinical trials. We assessed regulatory characteristics (approval date, approved drug[s], cancer type, line of therapy and biomarker‐restricted approval criteria) of each approval. Clinical trials leading to approvals were reviewed for trial design (RCT vs single arm study, primary endpoint) and PD‐L1 defined subgroup design (no subgroup analysis, single threshold 2‐group analysis, nested subgroups and adjacent subgroups). We then compared regulatory and trials characteristics (trial design, primary endpoint and biomarker approval criteria) between studies with nested and adjacent subgroups. There were 60 approvals for PD‐1/PD‐L1 inhibitors between January 2014 and December 2020. Twelve of 60 (20%) did not include any PD‐L1 subgroups. Twenty‐five of 60 (42%) approvals reported only two subgroups, 14 (23%) included adjacent subgroups and 9 (15%) had nested subgroups. Twenty‐five of 60 trials (42%) are single arm studies. Comparison of characteristics between trials with nested subgroup design and adjacent subgroup design did not show differences. We conclude that approvals for new indications of PD‐1/PD‐L1 inhibitors are based on studies that do not include comprehensive reporting of outcomes by PD‐L1 biomarker subgroups.